Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 19c
August 8, 2017 4:16 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $2.56, $0.19 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $394.4 million versus the consensus estimate of $410.82 million.
"Thus far, 2017 has been a highly productive year. We have executed on and delivered results of key... More
